Target
ARID1A
26 abstracts
Abstract
Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer.Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, CHA University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers.Org: Cancer Research UK National Biomarker Centre, Royal United Hospitals Bath NHS Foundation Trust, Torbay and South Devon NHS Foundation Trust, Velindre University NHS Trust, Clatterbridge Centre for Oncology NHS Foundation Trust,
Abstract
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.Org: Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Chris O'Brien Lifehouse, Royal North Shore Hospital, Sydney, Australia, Westmead Cancer Care Centre,
Abstract
ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch),
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.Org: Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China,
Abstract
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Maryland Capital Region, Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Kansas Cancer Center, Kansas City, KS,
Abstract
Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.Org: Foundation Medicine, Inc., Cambridge, MA, National Cancer Institute, Vilnius, Lithuania,
Abstract
Genomic characterization of somatic mutations by race and ethnicity in pancreatic cancer defined through AACR project GENIE.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Comprehensive characterization of androgen receptor expression in breast cancer.Org: Caris Life Sciences, Irving, TX, City of Hope National Medical Center, Washington University School of Medicine in St Louis, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
Clinical genomic implications of transcriptional subtypes in pancreatic cancer.Org: Dana-Farber Cancer Institute, Brookline, MA, Boston, MA, Caris Life Sciences, Irving, TX, Phoenix, AZ,
Abstract
Comprehensive profiling of mutational signatures and machine learning and subtypes of homologous recombination deficiency.Org: Genome Insight Inc., Research Institute for Future Medicine, Division of Breast Surgery, Division of Breast and Endocrine Surgery, Samsung Medical Center,
Abstract
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.Org: Lifespan Health System, Providence, RI, Ohio State University Comprehensive Cancer Center, Columbus, OH, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
The clinical feasibility of circulating tumor DNA alterations in patients with advanced hepatocellular carcinoma.Org: Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, CHA Bundang Medical Center, CHA University School of Medicine, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Medical Oncology Group,
Abstract
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).Org: University of Kansas Cancer Center, Kansas City, KS, Westwood, The University of Kansas Medical Center, Kansas City, MO, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.Org: H. Lee Moffitt Cancer Center and Research Institute, Predicine, Inc., Predicine Inc., Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute,
Abstract
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,
Abstract
Phase I/II study of nab-paclitaxel combined with S-1 as adjuvant chemotherapy in diffuse type of stage III gastric or gastroesophageal junction adenocarcinoma.Org: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China, Department of Oncology, Cancer center, Zhongshan Hospital, Fudan University, Shanghai, China,
Abstract
A pilot study evaluating somatic mutational burden and signatures among endometrial cancer patients: Is there prognostic benefit to whole genome sequencing?Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Nykode Therapeutics, Cornell University, Morehouse School of Medicine,
Abstract
Molecular profile of SWI/SNF complex in Chinese patients with ovarian cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd Nanjing, China, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
The impact of DNA damage repair gene mutations on therapeutic response among Chinese patients diagnosed with advanced biliary tract cancer.Org: Gastric Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy,
Abstract
Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced esophageal cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji Universtity School of Medicine,
Abstract
Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.Org: Triesta Sciences, HCG Cancer Center Mumbai, Strand Life Sciences,
Abstract
The mutational landscape of circulating cell free DNA in patients with gastric cancer.Org: The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Oncology,Daqing Oilfield Hospotal, Harbin, China, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, HaploX Biotechnology, Shenzhen, China, China-Japan Union Hospital of Jilin University, Jilin, China,
Abstract
Genome sequencing-based prognosis, mutational analysis, and survival rate of clear cell renal cell carcinoma.Org: University of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines, Tianjin University of Chinese Medicine, Tianjin, China, Montefiore Medical Center, Bronx, NY, Batterjee Medical College, Jeddah, Saudi Arabia, Houston Methodist Hospital, Houston, TX,
Abstract
A DMBA-induced ovarian cancer model: Could it be clinically useful to test OncoTherad and erythropoietin as anticancer approaches?Org: Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM), Department of Structural and Functional Biology, Institute of Biology-University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM), Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy, Institute of Biology - University of Campinas (UNICAMP), Campinas, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM), Institute of Biology - University of Campinas – UNICAMP, Campinas, Brazil, Nanomedicine Research Unit (Nanomed), Federal University of ABC (UFABC), Santo André, Brazil, Laboratory of Urogenital Carcinogenesis and Immunotherapy (LCURGIM), Department of Structural and Functional Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil, British Columbia’s Gynecological Cancer Research (OVCARE) Program and Department of Obstetrics and Gynecology, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada,